<DOC>
	<DOC>NCT01222013</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, through molecular response and event-free survival, about the use of Imatinib in conjunction with chemotherapy after BFM "like" Induction in children with ALL Ph+.</brief_summary>
	<brief_title>Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1. Diagnose: therapynaïve ALL, except for patients that performed Induction for ALL (33 days) exactly as this protocol and; documented Ph+, to be confirmed by conventional cytogenetic t(9;22) (q34;q11) or FISH and/or gene BCRABL presence by RTPCR or FISH. 2. Female patients of childbearing age, should have pregnancy test (blood βhCG) performed before treatment initiation. Effective contraception must be used during treatment. Pregnant women won't be included. 3. Life expectation &gt; 8 weeks. 4. Medications: antineoplastic treatmentnaïve, including corticotherapy, except for patients that performed Induction for ALL (33 days) exactly as this protocol. 5. Signed ICF by child legal responsible. 6. Laboratory: renal function (serum creatinine ≤ 1,5 x ULN and/or Clearance ≥70 ml/min/1,73m2), hepatic function (total bilirubin ≤ 1,5 x ULN, TGP/TGO &lt; 10 x ULN and albumin &gt; 2 g/dl. 1. Any inclusion criteria missing. 2. Pregnant patient or breastfeeding. 3. Patient considered incapable to follow purposed treatment. 4. Subject with infectious process, in activity, grade IV.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>